ArticlePloS one2016
Euterpe oleracea Extract (Açaí) Is a Promising Novel Pharmacological Therapeutic Treatment for Experimental Endometriosis.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Pharmaceuticals targeting signaling pathways of endometriosis as potential new medical treatment: A review.Medicinal research reviews · 2021Pooled it
- Endometriosis: New Perspective for the Diagnosis of Certain Cytokines in Women and Adolescent Girls, as Well as the Progression of Disease Outgrowth: A Systematic Review.International journal of environmental research and public health · 2021Pooled it
- Anticancer potential, molecular mechanisms and toxicity of Euterpe oleracea extract (açaí): A systematic review.PloS one · 2018Pooled it
- Natural bioactive compounds and herbal medicines targeting common signaling pathways in endometriosis: mechanisms and therapeutic implications.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- A Narrative Review of the Expression and Role of Nitric Oxide in Endometriosis.Antioxidants (Basel, Switzerland) · 2025Review
- A GREB1-steroid receptor feedforward mechanism governs differential GREB1 action in endometrial function and endometriosis.Nature communications · 2024Article
- Review
- Exotic fruits patents trends: An overview based on technological prospection with a focus on Amazonian.Heliyon · 2023Article
- Euterpe oleracea extract (açaí) exhibits cardioprotective effects after chemotherapy treatment in a breast cancer model.BMC complementary medicine and therapies · 2023Article
- Ethanol extract of basil (Journal of medicine and life · 2023Article
- Açaí (Nutrients · 2023Review
- Network pharmacology and experimental validation to explore the potential mechanism of Sanjie Zhentong Capsule in endometriosis treatment.Frontiers in endocrinology · 2023Article
- Metformin Alleviates Endometriosis and Potentiates Endometrial ReceptivityFrontiers in pharmacology · 2022Article
- The Role of Matrix Metalloproteinases in Endometriosis: A Potential Target.Biomolecules · 2021Review
- Antiangiogenic and Antioxidant In Vitro Properties of Hydroethanolic Extract from açaí (Molecules (Basel, Switzerland) · 2021Article
- An Overview on the Conservative Management of Endometriosis from a Naturopathic Perspective: Phytochemicals and Medicinal Plants.Plants (Basel, Switzerland) · 2021Review
- The Use ofBiomolecules · 2020Review
- Biomarkers for the Noninvasive Diagnosis of Endometriosis: State of the Art and Future Perspectives.International journal of molecular sciences · 2020Review
- Antibiotic therapy with metronidazole reduces endometriosis disease progression in mice: a potential role for gut microbiota.Human reproduction (Oxford, England) · 2019Article
- The value of the Brazilian açai fruit as a therapeutic nutritional strategy for chronic kidney disease patients.International urology and nephrology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigated the therapeutic potential of Euterpe oleracea extract (açaí) on the growth and survival of endometriotic lesions using an experimental model. Twenty female Sprague-Dawley rats were randomized into two groups after the implantation and establishment of autologous endometrium onto the peritoneum abdominal wall and treated with 200 mg/kg hydroalcoholic solution extract from açaí stone or vehicle via gastric tube for 30 consecutive days. Body weight, lesion surface areas, histological and immunohistochemistry analyses of vascular endothelial growth factor (VEGF), VEGF receptor-2 (VEGFR-2), metalloproteinase-9 (MMP-9), cyclooxygenase-2 (COX-2) and F4-80 were performed. Levels of VEGF, VEGFR-2, MMP-9 and COX-2 mRNA were measured. Flow cytometry of F4-80 was performed, and ELISA immunoassays measured prostaglandin E2 (PGE2), VEGF and nitric oxide (NO) and concentrations. Macrophage cell line J774.G8 was treated with 10, 20, and 40 μg/mL of açaí for 24, 48 and 72 h, and cell viability was measured using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays. Açaí treatment significantly decreased the implant size, and histological examination indicated atrophy and regression. A reduction in immunostaining and mRNA expression of VEGF, MMP-9 and COX-2 was observed, and F4-80 was lower in the treated group than the control group. The treated group also exhibited lower concentrations of PGE2, VEGF and NO compared to the control group. Macrophages cells treated with 20 and 40 μg/ml of açaí reduced cell viability in about 50% after 24, 48 and 72 h. Our results suggest that açaí effectively suppressed the establishment and growth of endometriotic lesions, and this agent is a promising novel pharmacological therapeutic treatment for endometriosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.